HomeInsightsStock Comparison

Alivus Life Sciences Ltd vs Astrazeneca Pharma India Ltd Stock Comparison

Alivus Life Sciences Ltd vs Astrazeneca Pharma India Ltd Stock Comparison

Last Updated on: May 21, 2025

Key Highlights

  • The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 1122 as of 21 May 10:40.
  • The P/E Ratio of Alivus Life Sciences Ltd changed from 13.4 on March 2022 to 20.2 on March 2024 . This represents a CAGR of 14.66% over 3 yearsThe P/E Ratio of Astrazeneca Pharma India Ltd changed from 82.8 on March 2020 to 82.4 on March 2024 . This represents a CAGR of -0.10% over 5 years.
  • The Market Cap of Alivus Life Sciences Ltd changed from ₹ 5624 crore on March 2022 to ₹ 9499 crore on March 2024 . This represents a CAGR of 19.09% over 3 yearsThe Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 5978 crore on March 2020 to ₹ 13301 crore on March 2024 . This represents a CAGR of 17.34% over 5 years.
  • The revenue of Alivus Life Sciences Ltd for the Mar '25 is ₹ 659.63 crore as compare to the Dec '24 revenue of ₹ 652.3 crore. This represent the growth of 1.12% The revenue of Astrazeneca Pharma India Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 448.27 crore. This represent the decline of -100%.
  • The ebitda of Alivus Life Sciences Ltd for the Mar '25 is ₹ 208.52 crore as compare to the Dec '24 ebitda of ₹ 200.76 crore. This represent the growth of 3.87% The ebitda of Astrazeneca Pharma India Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 51.42 crore. This represent the decline of -100%.
  • The net profit of Alivus Life Sciences Ltd changed from ₹ 135.45 crore to ₹ 141.87 crore over 8 quarters. This represents a CAGR of 2.34% The net profit of Astrazeneca Pharma India Ltd changed from ₹ 53.86 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% .
  • The Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 58.56 % on March 2024 . This represents a CAGR of -1.60% over 3 yearsThe Dividend Payout of Astrazeneca Pharma India Ltd changed from 3.46 % on March 2020 to 37.15 % on March 2024 . This represents a CAGR of 60.76% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Alivus Life Sciences Ltd

  • Glenmark Life Sciences Limited was incorporated as Zorg Laboratories Private Limited', on June 23, 2011 at Pune and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra at Pune.
  • Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' dated 10 August 2018.
  • A shareholders' resolution was passed on 13 August 2018 to convert the Company from a Private Limited Company to a Public Limited Company and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited.
  • The Company acquired API Division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January, 2019.

About Astrazeneca Pharma India Ltd

  • AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
  • The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
  • The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
  • Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

Alivus Life Sciences Ltd News Hub

News

Board of Alivus Life Sciences recommends final dividend

Alivus Life Sciences announced that the Board of Directors of the Company at its meeting h...

Read more

16 May 2025 09:27

News

Alivus Life Sciences to hold board meeting

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 15 Ma...

Read more

09 May 2025 10:57

News

Alivus Life Sciences allots 92,096 equity shares under ESOS

Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Conseq...

Read more

30 Apr 2025 19:38

News

Alivus Life jumps after Q3 PAT climbs 15% YoY to Rs 137 cr

Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25. For Q3FY25, EBIT...

Read more

23 Jan 2025 15:01

News

Alivus Life Sciences Ltd leads gainers in 'A' group

Avantel Ltd, Sunteck Realty Ltd, Spandana Sphoorty Financial Ltd and Jai Corp Ltd are amon...

Read more

21 Jan 2025 12:00

News

Glenmark Life Sciences renamed as Alivus Life Sciences

Glenmark Life Sciences announced its change of identity to Alivus Life Sciences, marking a...

Read more

20 Jan 2025 10:18

Astrazeneca Pharma India Ltd News Hub

News

AstraZeneca Pharma gets CDSCO nod to import and distribute TAGRISSO (Osimertinib)

The newly approved indication allows Osimertinib to be used in combination with pemetrexed...

Read more

05 Apr 2025 14:43

News

Astrazeneca Pharma gains after receiving approval from CDSO to import Durvalumab solution.

Through this approval, Durvalumab in combination with Tremelimumab is indicated for the tr...

Read more

03 Mar 2025 14:43

News

Astrazeneca Pharma gains after Q3 PAT soars to Rs 55 cr

Revenue from operations jumped 44% to Rs 440.29 crore in Q3 FY25 as compared with Rs 305.7...

Read more

12 Feb 2025 11:47

News

Astrazeneca Pharma India to hold board meeting

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 1...

Read more

21 Jan 2025 10:45

News

Volumes spurt at Astrazeneca Pharma India Ltd counter

Happiest Minds Technologies Ltd, Campus Activewear Ltd, Cera Sanitaryware Ltd, ITI Ltd are...

Read more

30 Dec 2024 14:30

News

AstraZeneca gets CDSCO nod to import cancer drug, Lynparza

This approval establishes the use of Olaparib in combination with Durvalumab as a maintena...

Read more

26 Nov 2024 14:49

SWOT Analysis Of Alivus Life Sciences Ltd

Strength

2

S

Weakness

2

W

Opportunity

1

O

Threats

0

T

BlinkX Score for Astrazeneca Pharma India Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Alivus Life Sciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Alivus Life Sciences Ltd and Astrazeneca Pharma India Ltd

Which company has a larger market capitalization, Alivus Life Sciences Ltd or Astrazeneca Pharma India Ltd?

Market cap of Alivus Life Sciences Ltd is 13,615 Cr while Market cap of Astrazeneca Pharma India Ltd is 19,802 Cr

What are the key factors driving the stock performance of Alivus Life Sciences Ltd and Astrazeneca Pharma India Ltd?

The stock performance of Alivus Life Sciences Ltd and Astrazeneca Pharma India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alivus Life Sciences Ltd and Astrazeneca Pharma India Ltd?

As of May 21, 2025, the Alivus Life Sciences Ltd stock price is INR ₹1110.3. On the other hand, Astrazeneca Pharma India Ltd stock price is INR ₹7920.85.

How do dividend payouts of Alivus Life Sciences Ltd and Astrazeneca Pharma India Ltd compare?

To compare the dividend payouts of Alivus Life Sciences Ltd and Astrazeneca Pharma India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions